Spanish Registry of Esophagogastric Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorFundación Sociedad Española de Oncologia Médica
About this trial
This study aims to development of a database through a web page for epidemiological and clinical research purposes that is accessible to members of the AGAMENON - SEOM group that guarantees a rigorous collection, exploitation and analysis of the data and information contained, increases the knowledge of esophageal and stomach cancer in order to optimize the management, treatment and evolution of patients, the possibility of comparing variables with those of other series or groups, and promotes the quality of scientific publications.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patient (≥18 years) diagnosed with carcinoma of the esophagus, gastroesophageal junction and stomach, including all histologic subtypes, with or without erbB2 overexpression (and tumors in which this data is unknown).
Follow-up of at least 3 months with clinical information during this period, exempting patients with early death from any cause.
Disqualifiers
A patient for whom, for whatever reason, the information necessary to complete the database cannot be known or obtained.
Trial population
The study plans to enroll patients with histologically confirmed carcinoma of the esophagus, gastroesophageal junction, and stomach. The inclusion of patients is required to be done consecutively, being valid any time point if data are available.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Surgery
Procedure/SurgerySurgery
Chemotherapy, anti-targeted agents and immunotherapy
DrugChemotherapy, anti-targeted agents and immunotherapy
Radiotherapy
RadiationRadiotherapy
Treatment groups
10,000 Participants
are divided into 2 treatment groupsGroup A: Cohort 13 interventions
Group B: Cohort 23 interventions
Trial outcomes
Primary outcomes
1
Diagnostic and therapeutic approach
To evaluate survival (time in months) according to treatment of esophagogastric cancer in all stages, patients, and contexts.
Time frame
Up to 12 monthsSecondary outcomes
1
Epidemiological profiles
To know the epidemiological profiles of esophagogastric cancer in Spain: temporal and regional trends, morbidity, and mortality.
Time frame
Up to 12 months2
Risk factors
To study risk factors associated with each subtype of esophagogastric cancer and localization.
Time frame
Up to 12 months3
Pathological features
To evaluate the pathological features (TNM, grade, histological response) The TNM is measured with the American Joint Committee on Cancer (AJCC) staging system. The grade is classified with the WHO scale. Histological response is measured with Becker classification.
Time frame
Up to 12 months4
Clinical and diagnostic approach
To know the diagnostic approch according to the center, type of studies performed: endoscopy, CT, echoendoscopy and/or PET/CT. From these studies it will be collected whether they have been carried out and where they visualise tumour. The use of scales and measurements is therefore not appropriate.
Time frame
Up to 12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov